The Food and Drug Administration yesterday approved a new antibiotic to treat adults with community-acquired bacterial pneumonia. The antibiotic, Xenleta, received priority review under an FDA Safety and Innovation Act designation for drug products intended to treat serious or life-threatening infections. About 1 million people are hospitalized with community-acquired pneumonia annually in the United States. “For managing this serious disease, it is important for physicians and patients to have treatment options,” said Ed Cox, M.D., director of FDA’s Office of Antimicrobial Products. “This approval reinforces our ongoing commitment to address treatment of infectious diseases by facilitating the development of new antibiotics.”  
 

Related News Articles

Headline
The AHA today commented on provisions related to surprise medical billing legislation that the House Education and Labor Committee could consider soon.
Headline
The Centers for Disease Control and Prevention today activated its Emergency Operations Center to enhance the inter-agency response to the outbreak of lung…
Headline
Transportation Secretary Elaine Chao last week named a committee to advise Congress and the departments of Health and Human Services and Transportation on…
Headline
NASEM will hold a public workshop Sept. 19 on population health improvement models.
Headline
Thirty-three states and the U.S. Virgin Islands have reported more than 450 possible cases of lung illness associated with using e-cigarette products,…
Headline
The Centers for Disease Control and Prevention last week issued a health advisory with information on the multistate outbreak of severe pulmonary disease…